JP2019526274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526274A5 JP2019526274A5 JP2019524114A JP2019524114A JP2019526274A5 JP 2019526274 A5 JP2019526274 A5 JP 2019526274A5 JP 2019524114 A JP2019524114 A JP 2019524114A JP 2019524114 A JP2019524114 A JP 2019524114A JP 2019526274 A5 JP2019526274 A5 JP 2019526274A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- protein
- fusion protein
- msp3
- antigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims 17
- 108020001507 fusion proteins Proteins 0.000 claims 17
- 230000000890 antigenic effect Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 5
- 101100373503 Enterobacteria phage T4 y06Q gene Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- HCUVEUVIUAJXRB-UHFFFAOYSA-N OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC Chemical compound OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC HCUVEUVIUAJXRB-UHFFFAOYSA-N 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 241001040659 Plasmodium (Plasmodium) Species 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 241000224016 Plasmodium Species 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 1
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 claims 1
- 101100024442 Anaplasma marginale msp4 gene Proteins 0.000 claims 1
- 101100301559 Bacillus anthracis repS gene Proteins 0.000 claims 1
- 101100247969 Clostridium saccharobutylicum regA gene Proteins 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 claims 1
- 101100373502 Enterobacteria phage T4 y06P gene Proteins 0.000 claims 1
- 101100412434 Escherichia coli (strain K12) repB gene Proteins 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 101100114425 Streptococcus agalactiae copG gene Proteins 0.000 claims 1
- 101150078331 ama-1 gene Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000925 erythroid effect Effects 0.000 claims 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 101150044854 repA gene Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 102200139497 rs2274268 Human genes 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022085159A JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16180544 | 2016-07-21 | ||
| EP16180544.5 | 2016-07-21 | ||
| PCT/SG2017/050369 WO2018017020A1 (en) | 2016-07-21 | 2017-07-21 | Biofusion proteins as anti-malaria vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022085159A Division JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526274A JP2019526274A (ja) | 2019-09-19 |
| JP2019526274A5 true JP2019526274A5 (OSRAM) | 2020-08-27 |
Family
ID=56550732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524114A Pending JP2019526274A (ja) | 2016-07-21 | 2017-07-21 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
| JP2022085159A Active JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022085159A Active JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210038706A1 (OSRAM) |
| EP (2) | EP3487526B1 (OSRAM) |
| JP (2) | JP2019526274A (OSRAM) |
| KR (2) | KR20190090775A (OSRAM) |
| CN (1) | CN109963586B (OSRAM) |
| AU (1) | AU2017300965B2 (OSRAM) |
| BR (1) | BR112019001115A2 (OSRAM) |
| CA (1) | CA3031399A1 (OSRAM) |
| TW (1) | TWI780058B (OSRAM) |
| WO (1) | WO2018017020A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3104833A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| WO2020033398A1 (en) * | 2018-08-06 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating atii cell-dependent lung diseases |
| WO2020104690A1 (en) * | 2018-11-23 | 2020-05-28 | Quine Medical Ab | Bi-specific conjugates |
| WO2020217226A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
| NL2023863B1 (en) * | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
| CN111135290A (zh) * | 2020-01-16 | 2020-05-12 | 定山石生物科技(北京)有限公司 | 一种用于激活人体免疫细胞的多肽试剂 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CA3203705A1 (en) | 2021-01-22 | 2022-07-28 | Erik Hans MANTING | Methods of tumor vaccination |
| BE1029148B1 (fr) * | 2021-02-26 | 2022-09-26 | Curavac Europe | Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave |
| CN118207228B (zh) * | 2024-03-21 | 2025-03-14 | 中国科学院上海免疫与感染研究所 | 一种防治结合的多时期双靶点串联疟疾mRNA疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3158900A (en) * | 1999-02-25 | 2000-09-14 | Smithkline Beecham Biologicals (Sa) | Immunogens comprising a peptide and a carrier derived from h.influenzae protein |
| DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| US20050112133A1 (en) * | 2003-10-24 | 2005-05-26 | Pierre Druilhe | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it |
| EP2460813A1 (en) * | 2003-12-17 | 2012-06-06 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
| WO2012163289A1 (zh) * | 2011-06-01 | 2012-12-06 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
| WO2014136064A2 (en) * | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
-
2017
- 2017-07-21 CN CN201780051251.4A patent/CN109963586B/zh active Active
- 2017-07-21 AU AU2017300965A patent/AU2017300965B2/en active Active
- 2017-07-21 KR KR1020197005103A patent/KR20190090775A/ko not_active Ceased
- 2017-07-21 EP EP17746213.2A patent/EP3487526B1/en active Active
- 2017-07-21 CA CA3031399A patent/CA3031399A1/en not_active Abandoned
- 2017-07-21 US US16/319,078 patent/US20210038706A1/en not_active Abandoned
- 2017-07-21 EP EP22182920.3A patent/EP4147715A1/en active Pending
- 2017-07-21 WO PCT/SG2017/050369 patent/WO2018017020A1/en not_active Ceased
- 2017-07-21 TW TW106124623A patent/TWI780058B/zh active
- 2017-07-21 KR KR1020247034516A patent/KR20240154691A/ko active Pending
- 2017-07-21 BR BR112019001115A patent/BR112019001115A2/pt unknown
- 2017-07-21 JP JP2019524114A patent/JP2019526274A/ja active Pending
-
2022
- 2022-05-25 JP JP2022085159A patent/JP7579298B2/ja active Active
- 2022-07-06 US US17/858,642 patent/US20220409712A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526274A5 (OSRAM) | ||
| US11771755B2 (en) | Self-asssembling nanostructure vaccines | |
| Smith et al. | Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications | |
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| Stover et al. | Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. | |
| JP2023524054A (ja) | ベータコロナウイルスの予防と治療 | |
| JP2015509707A5 (OSRAM) | ||
| US8580274B2 (en) | Drug transporter, and adjuvant and vaccine each utilizing same | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| CN113301918A (zh) | Cmv的通过融合修饰的病毒样颗粒 | |
| ES2236718T3 (es) | Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna. | |
| Haeuw et al. | The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides | |
| JPH10509325A (ja) | 粘膜免疫を刺激する免疫原 | |
| Shivachandra et al. | Immunogenicity of recombinant Omp16 protein of Pasteurella multocida B: 2 in mouse model | |
| AU2022366884A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
| WO2019228032A1 (zh) | 磷酸化多肽抗原疫苗及其制备方法和应用 | |
| TWI683668B (zh) | 用於免疫作用中有效抗體生産的新穎蛋白質結構 | |
| CN113801206A (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
| Ohtake et al. | Recombinant therapeutic protein vaccines | |
| JP2000000099A (ja) | ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体 | |
| CN106337038B (zh) | 一种通过转肽酶剪切制备疫苗的方法及其应用 | |
| US11535651B2 (en) | Hepatitis B nanoparticle-based vaccine for influenza virus | |
| CN116813793B (zh) | 融合蛋白以及其应用 | |
| JP6590916B2 (ja) | 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト | |
| RU2845190C2 (ru) | Вирусоподобные частицы cmv, модифицированные путем слияния |